Retatrutide is the most advanced weight-loss peptide in research — activating three receptors simultaneously for fat-loss results that exceed Ozempic and Tirzepatide. Phase 2 trials showed up to 24% body weight reduction in 48 weeks. The next generation is here.
Retatrutide is a single synthetic peptide that activates three receptors at once — the GLP-1 receptor (the Ozempic target), the GIP receptor (the Mounjaro addition), and the glucagon receptor. No approved drug does this yet. And the results speak for themselves: Phase 2 trials published in the New England Journal of Medicine showed up to 24% body weight reduction over 48 weeks — substantially more than any approved GLP-1 or dual agonist.
Here's why the triple combination works better. GLP-1R suppresses appetite and stabilizes blood sugar. GIP receptor activation improves insulin sensitivity and modulates fat storage. The glucagon receptor — the novel addition — increases energy expenditure by driving thermogenesis and fat burning. In isolation, glucagon raises blood sugar. But combined with the insulin-promoting effects of GLP-1R and GIPR, that glucose effect is neutralised, while the energy expenditure benefit is preserved. The result: caloric deficit from two directions simultaneously.
Retatrutide is currently in Phase 3 clinical trials. For researchers, it's the most powerful available tool for studying the obesity-related metabolic receptor landscape and the synergistic effects of multi-receptor co-activation. Sharp Labs supplies it as lyophilized powder at ≥98% HPLC purity, with Certificate of Analysis included.
COA INCLUDED — SHIPPED WITHIN 48H — EUROPE-WIDE DELIVERY
Message @Sharp_Rebot →